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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) has infected more than 40 million
people worldwide, mainly in sub-Saharan Africa. The high prevalence of HIV-1 subtype C in
southern Africa necessitates the development of cheap, effective vaccines. One means of
production is the use of plants, for which a number of different techniques have been successfully
developed. HIV-1 Pr55Gag is a promising HIV-1 vaccine candidate: we compared the expression of
this and a truncated Gag (p17/p24) and the p24 capsid subunit in Nicotiana spp. using transgenic
plants and transient expression via Agrobacterium tumefaciens and recombinant tobamovirus
vectors. We also investigated the influence of subcellular localisation of recombinant protein to the
chloroplast and the endoplasmic reticulum (ER) on protein yield. We partially purified a selected
vaccine candidate and tested its stimulation of a humoral and cellular immune response in mice.
Results: Both transient and transgenic expression of the HIV antigens were successful, although
expression of Pr55Gag was low in all systems; however, the Agrobacterium-mediated transient
expression of p24 and p17/p24 yielded best, to more than 1 mg p24/kg fresh weight. Chloroplast
targeted protein levels were highest in transient and transgenic expression of p24 and p17/p24. The
transiently-expressed p17/p24 was not immunogenic in mice as a homologous vaccine, but it
significantly boosted a humoral and T cell immune response primed by a gag DNA vaccine,
pTHGagC.
Conclusion: Transient agroinfiltration was best for expression of all of the recombinant proteins
tested, and p24 and p17/p24 were expressed at much higher levels than Pr55Gag. Our results
highlight the usefulness of plastid signal peptides in enhancing the production of recombinant
proteins meant for use as vaccines. The p17/p24 protein effectively boosted T cell and humoral
responses in mice primed by the DNA vaccine pTHGagC, showing that this plant-produced protein
has potential for use as a vaccine.
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Background
The acquired immunodeficiency syndrome (AIDS) result-
ing from infection by human immunodeficiency virus
type 1 (HIV-1) is arguably the greatest medical and scien-
tific challenge to face humankind in the past decade. More
than 40 million people worldwide live with the virus, and
5 million were infected in 2004 alone. Two thirds of all
HIV-1 infections occur in sub-Saharan Africa and the epi-
demic is still spreading at unprecedented rates [1].
It has been proposed that the only means of halting this
epidemic will be the introduction of a large-scale immu-
nisation programme, preferably using cheaply-produced
vaccines. There are numerous vaccine initiatives currently
in progress globally [2], but the number of different sub-
types of HIV-1 prevalent in different geographic areas has
complicated the prospects for a universal HIV-1 vaccine.
HIV-1 subtype C is the predominant HIV in southern
Africa; therefore, South African isolates of this subtype
have been used in the development of candidate DNA and
other virally- and bacterially-vectored and subunit vac-
cines for South Africa under the auspices of the South Afri-
can AIDS Vaccine Initiative (SAAVI) [3-5]. Because of the
extent of HIV-1 infection in southern Africa, any immuni-
sation programme will require enormous quantities of
vaccine. DNA vaccines are expensive to manufacture, as
are recombinant viral and subunit vaccines produced via
cell culture. This makes the proposition costly and possi-
bly unfeasible, particularly for the poorer developing
countries where HIV infection is prevalent. There is there-
fore a strong need to develop vaccine expression systems
which have the potential to produce vaccines at low cost
for these countries.
One of the cheapest possible means of producing subunit
vaccines is via plants [6-9]. Expression hosts include crop
plants such as Nicotiana tabacum (tobacco) and other
Nicotiana spp., alfalfa, rice, wheat, potato and soybeans,
amongst a number of others. Different expression systems
include transient viral vector expression [10-15], Agrobac-
terium tumefaciens-mediated transient expression [16-18],
and the generation of stable transgenic plants [19-21] or
cultured plant cells [22] expressing the protein of interest.
The majority of plant-produced recombinant proteins
have been produced by transgenic plants, and in many
cases, transplastomic plants [23]. However, transient
expression is a viable alternative: the short production
cycle coupled with codon optimisation, suitable promot-
ers and the help of silencing suppressors such as plant
virus-derived p19 and NSs [18] means that it can be scaled
up to produce high protein yields in a very short time [7].
There are several advantages to using plant-produced vac-
cine antigens: there is proper protein folding equivalent to
other eukaryotic systems, the raw material cost is lower,
the process is highly scalable, large amounts can be pro-
duced at relatively low cost, multiple vaccines may be pro-
duced together and they may be expressed in edible plant
organs, which would make oral delivery convenient [7,24-
26]. However, poor expression levels in transgenic plants
and the complex regulatory problems surrounding plant-
produced vaccines are the major challenges [27]. Moreo-
ver, reports of inadvertent mixing into the food chain of
pharmaceutical proteins from transgenic plants in the
USA [28] have put transient plant expression into the
spotlight as a bona fide production strategy in its own
right.
The HIV-1 Gag precursor protein Pr55 Gag as well as pro-
teins p17 (MA or matrix protein) and p24 (CA or capsid
protein) resulting from cleavage of Pr55Gag by the viral
protease, are potentially good candidates for the develop-
ment of HIV subunit vaccines (see Figure 1). Pr55Gag
expressed in a variety of cell systems can assemble and
bud through the plasma membrane to form highly immu-
nogenic virus-like particles (VLPs) [29,30]. These VLPs are
non-infectious and morphologically similar to immature
HIV particles, stimulate potent cellular and humoral
The HIV-1 Gag-derived proteins used in this study Figure 1
The HIV-1 Gag-derived proteins used in this study. Scale diagram showing (A) native Pr55Gag ORF organisation in the 
gag gene, (B) the p17/p24 fusion protein ORF, (C) p24 ORF. ORFs labelled p7, p6 represent minor proteins.BMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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responses, and are safe to administer to animals and
humans [31]. Gag VLPs are a promising vaccine candidate
because Gag contains the highest density of cytotoxic T-
lymphocyte (CTL) epitopes of any HIV protein [32,33],
and cellular immune responses to Gag in infected people
are correlated with control of infections; they are highly
immunogenic and elicit Th1-biased responses in experi-
mental animals at low dosage levels [30]; they are rela-
tively stable, and they can easily be used as carriers for
other peptides [29]. The native p17 facilitates the intra-
membrane associations necessary for viral assembly and
release [34,35] as well as being involved in the transport
of the viral pre-integration complex into the nucleus [36].
It is well-documented that the risk of AIDS is greatly
increased in individuals with falling titres of p24 antibod-
ies [37-40], suggesting that high anti-p24 antibody titres
might be necessary to maintain a disease-free state. It is
also significant that p17 and p24 together contain the
highest density of cytotoxic T-lymphocyte (CTL) epitopes
of the HIV-1 proteome [33]. There are also indications
that p17/24 fusion proteins may form VLPs or tubular
structures [41], which could make them a good carrier for
immunogenic presentation of foreign epitopes.
Studies done on plant-expressed HIV-1 vaccines have
largely focused on HIV-1 Env epitopes fused to virus par-
ticles or other proteins, to produce chimaeric virus parti-
cles which have been tested for their ability to produce an
appropriate antibody response [42-46]. A few studies have
also been carried out using the Tat protein [47,48]. Zhang
et al. [49,50] showed that HIV-1 p24 could be expressed
as a fusion protein with tomato bushy stunt virus (TBSV)
capsid protein in tomatoes. However, the inserted p24
open reading frame (ORF) was not stably maintained. The
same researchers subsequently generated stable transgenic
N. tabacum expressing the same HIV-1 p24 protein at lev-
els of 0.35% of total soluble protein (TSP) [26]. More
recently, Pérez-Filgueira [50] et al. showed that a recom-
binant tobacco mosaic virus (TMV)-derived vector
expressing subtype C HIV-1 p24 in N. benthamiana yielded
levels of 100 mg per kg fresh leaf weight. Furthermore,
immunisation of rabbits using purified recombinant p24
induced a humoral response in inoculated rabbits that
was strong and specific to p24. However, there are no
studies reported to date on the expression of HIV-1
Pr55Gag or p17 in plants, and HIV-1 p24 is not seen by
many as a good vaccine candidate. While its expression in
plants has not been investigated, recombinant HIV-1 p17/
24 fusion protein has successfully been produced in insect
cells via recombinant baculovirus [41] for mapping
domains involved in VLP formation.
We have previously expressed HIV-1 subtype C isolate
Du422 Pr55Gag via recombinant baculovirus in insect
cells, and shown that it assembled and budded to form
VLPs, and that these were highly immunogenic in mice
[30]. In this study we explored and compared the use of
transient and transgenic plant expression systems for the
production of recombinant HIV-1 subunit proteins p24
and p24/p17 as well as of Pr55Gag and possibly VLPs. We
investigated the usefulness of codon optimisation and of
targeting recombinant proteins to the ER and chloroplasts
as a means of improving yields, and investigated whether
transient expression via recombinant tobamoviruses or
Agrobacterium tumefaciens produced better yields than the
Agrobacterium-engineered transgenic system. Finally, we
assessed both the cellular and humoral immune
responses to HIV-1 p17/p24 (one of the most highly-
expressed plant-produced HIV proteins) in mice inocu-
lated with this protein, in order to assess the viability of a
plant-produced HIV-1 vaccine.
Results
TMV vector expression
Expressed protein levels measured as μg p24/kg fresh leaf
weight using the TMV vector expression system are shown
in Table 1. Expression of full length Pr55Gag from the
wtgag  gene was almost undetectable (<0.01 μg p24/kg
fresh leaf wt) compared with Nicotiana spp. codon-opti-
mised ngag-expressed Pr55Gag levels, which ranged from
0.46 to 2.0 μg p24/kg fresh leaf wt. Expressed protein lev-
els from all three versions of the p24 gene (Nicotiana spp.-
Table 1: Yields of recombinant proteins obtained in Nicotiana spp. using the TMV expression system.
Recombinant protein (non-targeted) TMV Expression (μg p24/kg)
Full length Pr55Gag
wtgag <0.01
ngag 0.46 – 2.0
p24
wtp24 172 – 13900
np24 230 – 17350
hp24 167 – 1000
Levels of protein are expressed as μg p24 per kg of fresh leaf weight.
wt = wildtype codon usage; n = Nicotiana spp. codon-optimised; h = human codon-optimisedBMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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and human codon-optimised and wild type) were signifi-
cantly higher (100 to 10000 times greater) than the p24
levels obtained with gag, ranging from 167 to 17350 μg
p24/kg fresh leaf wt. Although plant-optimised np24
expression levels were the highest, with wtp24 expressed
protein levels being about 1.2 times and hp24 expressed
protein levels being at least 10 times less, p24 levels varied
considerably within the specific version tested. Despite
the low levels of recombinant protein expression, samples
of crude plant sap from N. benthamiana infected with the
pBSGngag recombinant TMV RNA that were immu-
notrapped with HIV-1 p17 antiserum and viewed under
the electron microscope, showed the presence of VLPs
approximately 110 to 120 nm in diameter (data not
shown). These were very similar in shape and size to bac-
ulovirus-produced Pr55Gag VLPs [30]. Plants infected
with rTMV expressing p24 did not produce any particles
(not shown). Given the very low yield of the Pr55Gag pro-
tein, however, these preliminary results were not followed
up.
A. tumefaciens-mediated transient expression
To investigate the possibility of expressing HIV-1 p24,
p17/24 and Pr55Gag in plants for vaccine purposes, three
sets of constructs encoding cytosol-retained, ER-targeted
or chloroplast-targeted proteins (Table 2), were generated
and agroinfiltrated into N. benthamiana plants. In addi-
tion, the effects of myristylation of p17/24 were investi-
gated, as this is known to affect the accumulation of
Pr55Gag in cells.
The expression of the recombinant proteins Pr55Gag, p24
and myristylated p17/p24 was measured using a p24 anti-
gen ELISA. A comparison of the three transient recom-
binant protein expression levels in N. benthamiama leaves
is shown in column A (Table 3). In leaf tissue that was
syringe-infiltrated with constructs expressing the cytosol-
retained proteins, p17/p24 was expressed at the highest
level compared with expression of both p24 and Pr55Gag
which were 10 times lower. In leaf tissue infiltrated with
ER-targeted constructs, p24 was expressed at the highest
level (ranging from 3700 to 16100 μg/kg) when com-
pared with expression of p17/p24 (200 μg/kg) and
Pr55Gag (8 to 13 μg/kg). In leaf tissue infiltrated with
chloroplast-targeted constructs, both p24 and myri-
stylated p17/p24 were expressed at similar levels (4000
μg/kg) when compared with expression of Pr55Gag (1 to
29 μg/kg). Overall, ER-targeted p24 and chloroplast-tar-
geted p24 and p17/p24 yielded p24 levels which were
greater than 1 mg/kg fresh weight. The expression of
Pr55Gag was low in all of the targeted intracellular sites.
No p24 antigen was detectable in plants infiltrated with
buffer only as the control.
We separately investigated the effect of removing the myr-
istylation signal on p17/p24 expression by comparing
G2A-mutated p17/24 (NM) and myristylated p17/24 (M)
protein expression (Figure 2). Removal of the signal
reduced cytosolic protein accumulation by 9-fold and ER
accumulation by only ~2 fold, but resulted in 50 to 70-
fold yield reduction for the chloroplast localised protein
when compared to the myristylated version, at 4 mg/kg.
Protein expression for the three non-myristylated p17/24
constructs (pTRA-Cp17/p24-NM, pTRA-CPTp17/p24-NM
and pTRA-ERp17/p24-NM) was highest in the ER (241
μg/kg), and about the same in cytoplasm and chloroplasts
(~60 μg/kg).
The western blot detection of transiently-expressed p17/
p24 protein in unfractionated leaf extracts is shown in Fig-
ure 3: the product is clearly visible, as a strong single band
of appropriate size, in extracts of plants where protein was
Table 2: Summary of the recombinant constructs used for Agrobacterium-mediated transient and transgenic expression.
Vector Subcellular Target Insert Clone
pTRAc cytosol p24 pTRA-Cp24
p17/p24 pTRA-Cp17/p24-M
pTRA-Cp17/p24-NM
gag pTRA-Cgag
pTRAkc-ERH ER p24 pTRA-ERp24
p17/p24 pTRA-ERp17/p24-M
pTRA-ERp17/p24-NM
gag pTRA-ERgag
pTRAkc-rbcS1-cTP chloroplast p24 pTRA-CPTp24
p17/p24 pTRA-CPTp17/p24-M
pTRA-CPTp17/p24-NM
gag pTRA-CPTgag
All genes were Nicotiana spp. codon-optimised
M = myristylated; NM = non-myristylatedBMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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targeted to the chloroplasts. In contrast, ER-targeted pro-
tein is barely visible as a band in adjacent lanes.
HIV antigen expression in transgenic N. tabacum
Expressed p24 protein levels from transgenic plants are
shown in column B (Table 3). No HIV-1 p24 protein was
detected in non-transgenic control samples. Eight trans-
genic plants expressing chloroplast-targeted p24 (np24C)
were regenerated. The highest p24 level measured was
about half of that reported for the corresponding tran-
siently-expressed protein. Three transgenic plants express-
ing ER-targeted and one expressing cytoplasm-targeted
p24 were regenerated. Expressed p24 levels ranged from
0.01 to 1.19 μg/kg fresh leaf wt for np24ER and 0.04 μg/
kg fresh leaf wt for np24C.
Five putative transgenic plants were generated for pTRA-
ERp17/p24-M and extracts from leaves of these plants
shown to have less than 1 μg/kg of p24 expressed in a pre-
liminary p24 ELISA screen (Table 3 column B). Eight
transgenic lines were generated from pTRA-CPTp17/p24-
M-producing transgenic plants. Preliminary screening
showed the expression of approximately 5 to 230 μg p24/
kg FW. No transgenic plants were generated from pTRA-
Cp17/p24-M. No product was amplified from control
plant genomic DNA.
Twenty-six transgenic plants expressing chloroplast-tar-
geted Pr55Gag were regenerated on kanamycin selection
medium. Recombinant protein levels (Table 3 column B)
were similar to those obtained with the corresponding
vectors in the transient expression studies which were gen-
erally low: these ranged from 0.03 to 48 μg p24/kg fresh
leaf wt. Twenty-eight transgenic plants expressing ER-tar-
geted Pr55Gag were regenerated with expressed protein
levels ranging from 0.13 to 7 μg p24/kg fresh leaf wt.
Although there were 8 cytoplasm-targeted Pr55Gag regen-
erants, these did not survive transplantation and harden-
ing off and we were not able to measure the p24
Table 3: Comparison of yields of recombinant HIV-1 p24, p17/24 and Gag proteins obtained in N. benthamiana by (A) A. tumefaciens-
mediated transient expression or (B) transgenic expression.
AB
Recombinant protein Transient Expression (μg p24/kg) Transgenic Expression (μg p24/kg)
Pr55Gag
GagC 7 – 44 D
GagER 8 – 13 0.13 – 7
GagCPT 1 – 29 0.03 – 48
p24
p24C 0.01 0.04
p24ER 3691 – 16148 0.01 – 1.19
p24CPT 937 – 4014 636 – 2994
p17/p24
p17/p24C 220 -
p17/p24ER 220 <1
p17/p24CPT 4800 5–230
Levels of protein are expressed as μg p24 per kg of fresh leaf weight. All genes were Nicotiana spp. codon-optimised.
C, ER and CPT in construct names indicate whether the protein remained in the cytosol, or was targeted to the endoplasmic reticulum or the 
chloroplast, respectively.
D: regenerants died during transplantation
-: no transgenic plants generated
Western blot analysis of HIV p17/24 from infiltrated N.  benthamiana leaves and fractionation of purified protein Figure 3
Western blot analysis of HIV p17/24 from infiltrated 
N. benthamiana leaves and fractionation of purified 
protein. Clarified sap samples were electrophoresed on a 
12% SDS-PA gel and blotted onto nylon membrane. The 
membrane was probed with a rabbit polyclonal anti-p24. M, 
molecular weight marker; Gag, HIV B Gag reference sample; 
C, extract from leaves infiltrated with infiltration buffer; ER1 
and ER2, extracts from two pTRA-ERp17/p24-M infiltrated 
leaves; CPT1 and CPT2, extracts from two pTRA-CPTp17/
p24-M infiltrated leaves.BMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
Page 6 of 15
(page number not for citation purposes)
expression levels. Overall, Pr55Gag expression was negli-
gible compared with that of p24 and p17/p24.
Cellular and humoral response of mice to the p17/p24 
(pTRAk-CPTp17/p24-M)
Although transiently-expressed ER-targeted p24 (p24ER)
on its own yielded the highest levels of p24 per kg FW
(Table 3 column A), it was decided to carry out immuno-
logical studies in mice using the chloroplast-targeted p17/
p24 protein (p17/p24CPT). From the point of view of
developing a candidate vaccine it provides a greater
number of epitopes for the induction of a broad immune
response. The possibility that this protein may form VLPs
or tubular structures also supports its use in immuno-
genicity studies [41]. Particulate p17/p24 protein is pro-
posed to be more effective in stimulating a cellular
immune response [51]. Partially-purified protein extract
fractionated by SDS-PAGE contained predominantly a
single polypeptide of the appropriate size (not shown).
The cellular immune response to p17/p24 partially-puri-
fied leaf protein was investigated in BALB/c mice, either
alone, or in a prime boost inoculation regimen where the
DNA vaccine pTHGagC was used to prime the immune
response and p17/p24 protein to boost this response. Cel-
lular responses were assayed by IFN-γ ELISPOT and anti-
body responses by ELISA and the specificity of the
antibodies confirmed using the New LAV Blot 1 western
blot kit.
For all groups of mice the average background responses
in the absence of peptide and to an irrelevant peptide was
not greater than 50 ± 6 sfu/106 splenocytes (Figure 4). The
strong response to a Gag CD8+ T cell peptide of 117 sfu/
106 splenocytes that was achieved with a single inocula-
tion of pTHGagC was increased 2.3 fold (p < 0.01) by a
booster inoculation with 64 ng of p17/p24 protein (Fig-
ure 4). No improvement in this response was achieved
when the dose was increased to 646 ng p17/p24 protein.
pTHGagC induced a weak response just above back-
ground to a Gag CD4+ T cell peptide, which was signifi-
cantly boosted (4.7 fold) by 64 ng p17/p24 protein to 209
sfu/106 splenocytes (p < 0.01). As seen with the response
to the CD8+ T cell peptide, a higher dose of p17/p24 pro-
tein did not increase the magnitude of the immune
response to the Gag CD4+ T cell peptide. These increases
in cellular immune responses to Gag induced by p17/p24
protein were specific, as there was no significant change in
the response to pTHGagC when control leaf protein was
used as the boost (Figure 4). Interestingly, the level of
response to the Gag CD8+ and CD4+ T cell peptides after
a prime with pTHGagC and boost with p17/p24 protein
was similar to that of two doses of pTHGagC (Figure 4).
The mice in groups 6 and 7 that were inoculated with the
p17/p24 protein alone showed no cellular immune
response to Gag above background, 12 days after inocula-
tion (Figure 4).
The humoral arm of the specific immune response to Gag
for the 8 groups of immunized mice was evaluated by
looking at serum anti-Gag total IgG and IgG subtypes (Fig-
ure 5A). Significant levels (p < 0.01) of Gag-specific total
IgG antibodies and IgG subtypes above those in the pre-
bleed serum were obtained for groups 1 – 5 inoculated
with either pTHGagC or primed with pTHGagC then
boosted with p17/p24 protein (Figure 5A).
The high levels of Gag-specific total IgG in response to
pTHGagC of 17 fold above background (p < 0.01)
increased 40 fold (p < 0.01) and 34 fold (p < 0.01) above
background when the mice were boosted with either 646
ng or 64 ng p17/p24 protein respectively (Figure 5A).
These differences in the level of Gag-specific total IgG elic-
ited by booster doses of 646 ng and 64 ng of p17/p24 pro-
tein were significant (p < 0.05) (Figure 5A).
Determination of Gag-specific serum IgG subtypes indi-
cated the presence of significant (p < 0.01) levels of IgG1,
IgG2a, IgG2b and IgG3 above background pre-bleed val-
ues (Figure 5A). Boosting pTHGagC primed mice with
pTHGagC or 64 ng leaf protein containing p17/p24 pro-
tein induced higher IgG2a than IgG1 levels whereas
boosting with 646 ng p17/p24 protein reversed this ratio
The effect of intracellular localisation on accumulation of  myristylated p17/24 Figure 2
The effect of intracellular localisation on accumula-
tion of myristylated p17/24. Transient expression of HIV-
1 p17/24 protein in Agrobacterium-infiltrated N. benthamiana 
was measured by HIV-1 p24 ELISA 4 days after infiltration.BMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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(Figure 5B). No Gag-specific antibodies above that in the
pre-bleed serum were obtained for groups 6 – 8 inocu-
lated with either dose of p17/p24 protein or control leaf
protein (data not shown).
A commercial western blot system for determining HIV-1
antibodies confirmed the presence of antibodies to Gag in
the serum of inoculated mice (Figure 6). In addition,
judged from the intensity of the bands on the strips, the
ability of p17/p24 to boost the antibody response
induced by pTHGagC is clearly visible.
Discussion
Our group has previously investigated the suitability of a
baculovirus-expressed HIV-1 Pr55 Gag virus-like particle
(VLP) preparation as a candidate HIV vaccine, in combi-
nation with a DNA gag vaccine [30]. Part of our objective
in this study was to investigate the feasibility of expressing
the same gene in plants via recombinant TMV as a cheaper
means of making VLPs. While a plant codon-optimised
version of the gene produced a Pr55Gag protein which
apparently formed recognisable VLPs (data not shown),
the yield of protein was extremely low. We investigated
whether yield could be improved by truncation or differ-
ential localisation of the protein, and showed that
sequences downstream of the p24 ORF negatively affected
expression, given that either p24 or p17/24 proteins were
expressed relatively well, both in transient and transgenic
expression systems. Interestingly, while expression of the
gag-derived genes used here did benefit from plant codon
optimisation, unlike our group's earlier experience with
Human papillomavirus type 16 (HPV-16) L1 protein
expression [52], as in that work we found that determina-
tion of best intracellular locale for transient protein accu-
mulation was strictly empirical. Thus, while Pr55Gag
accumulated similarly poorly in all locations, and p24
accumulated negligibly in cytoplasm and significantly
better in both the ER and chloroplasts, p17/p24 yield was
similar in cytoplasm and ER and 20-fold better in chloro-
plasts. Transgenic expression presented a different picture:
cytoplasmic targeting of Pr55Gag resulted in regeneration
failure, indicating toxicity; ER-targeted p24 did not accu-
mulate well, although chloroplast targeting was equiva-
lent to transient expression, and p17/p24 again
accumulated best in chloroplasts, but to 20-fold lower lev-
els than in transient studies.
We then investigated the feasibility of expressing HIV-1
p17/24 – a truncated Gag, but a more appropriate vaccine
candidate than p24 – in Nicotiana spp. at levels suitable for
processing for vaccine manufacture. We showed that tran-
siently expressing the transgene under the CaMV 35S pro-
moter produced the highest protein yields, up to 4 mg/kg
(~0.3% TSP). The protein seemed to be relatively stable in
IFN-γ ELISPOT analysis of Gag T cell responses after vaccination of BALB/c mice Figure 4
IFN-γ ELISPOT analysis of Gag T cell responses after vaccination of BALB/c mice. Inoculations with the indicated 
antigens were given as specified in the methods and all groups of mice were sacrificed on day 40. Reactions in the IFN-γ ELIS-
POT assay were done in triplicate with the indicated Gag peptides, an irrelevant peptide (irrel pept) or absence of peptide 
(Bkg) and bars are the average number of spot forming units (sfu) ± SD/106 splenocytes. Data are from a representative exper-
iment with splenocytes pooled from 5 mice per group.
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Gag-specific serum total IgG and IgG subtypes Figure 5
Gag-specific serum total IgG and IgG subtypes. Mouse groups were inoculated with the indicated antigens as specified in 
the methods and serum isolated on day 40 for antibody measurements by ELISA quantifying total IgG and IgG subtypes IgG1, 
IgG2a, IgG2b and IgG3 against Gag. Pooled serum samples from 5 mice per group were tested at 1:1000 dilution. (A) Bars rep-
resent the average absorbance ± SD for triplicate values, and represent the level of total IgG and IgG subtypes IgG1, IgG2a, 
IgG2b and IgG3 against Gag above pre-bleed absorbance values which were not more than 0.003. Ratio of absorbance values 
to prebleed values is shown on the right. (B) Ratio of IgG2a vs IgG1 for the indicated groups of mice.
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these studies; however, results from transgenic plants
showed higher recombinant protein yields in the young
leaves than in the older, suggesting active turnover in the
leaves rather than passive accumulation – in contrast to
results for production of HPV-16 L1 protein [52]. The
result clearly demonstrated that transient expression, and
in particular, targeting the protein of a nuclear gene to the
chloroplast, results in the best yield of recombinant p17/
p24.
The protein yields reported in this study were below the
expected economic threshold (1%). However, our labora-
tory has shown that up to 800 mg of HPV-16 L1 protein
per kg fresh weight (12–17% total soluble protein) can
accumulate in the chloroplasts of tobacco plants [52],
meaning there is potential for much higher level accumu-
lation.
Although results from electron microscopy were inconclu-
sive it could be speculated that the HIV-1 p17/24 protein
might form stable structures and possibly virus-like parti-
cles (VLPs), or tubules as reported by [41]. The myristyla-
tion site on the native Pr55Gag protein is essential for
targeting the HIV-1 Pr55Gag protein to the plasma mem-
brane: it is possible that myristylated p17/24 associates
with the chloroplast membranes to make higher-order
structures, and that non-membrane associated protein is
toxic, which could account very well for the drastic differ-
ence in yield of the native and non-myristylated versions
of p17/p24 (Figure 2). It is also possible that the mem-
brane-associated form could be useful as a carrier for
epitope presentation through C-terminal fusions, as is the
full Pr55Gag protein made in insect cells [29]. In any case,
further investigations are needed to characterise the
nature of the structure(s) formed from the protein
Western blot detection of Gag antibodies in mouse serum Figure 6
Western blot detection of Gag antibodies in mouse serum. The content of Gag antibody in mouse serum was 
detected using commercial western blot strips as described in the methods. +, positive control serum; -ve, negative control 
serum; S, mouse serum taken at day 40 after inoculation as indicated and described in methods; P, pre-inoculation mouse 
serum. The inoculation regimen for each set of strips is indicated above the strips: these were gag DNA prime – p17/p24 
boost; gag prime-gag boost; gag single inoculation; p17/p24 single inoculations.BMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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described here, and also its immunogenicity, if it is to be
used as a candidate HIV-1 vaccine.
This study focussed on the immune response of mice to
the leaf protein containing p17/p24 protein and was set
up as proof of concept that plant-produced HIV proteins
could possibly be further developed for candidate vac-
cines. As several studies have indicated enhanced immune
responses can be achieved by heterologous prime-boost
inoculation regimens, we chose to investigate the immune
response of p17/p24 alone and its ability to boost an
immune response to a DNA vaccine pTHGagC that is
known to prime an immune response of mice, which can
be effectively boosted by Pr55Gag VLPs [30]. Indeed, the
substantial boost by leaf protein containing p17/p24 pro-
tein of Gag-specific cellular and humoral immune
responses induced by the DNA vaccine pTHGagC suggests
that HIV proteins produced in plants may be very valuable
for expanding immune responses after the immune sys-
tem has been primed. While both CD8+ and CD4+ vac-
cine-specific T cells have a protective role, CD4+ T cells are
potentially important for the induction and maintenance
of CD8 memory cells and stimulation of B cells for anti-
body production [53-55]. We found the increase in Gag-
specific CD4+ T cells induced by the boost with p17/p24
protein is associated with a substantial increase in the
Gag-specific humoral responses and a progression in an
IgG1 to IgG2a isotype switch. Even though we did not
measure Gag-specific Th1–Th2 responses, the IgG iso-
types suggest our prime-boost inoculation regimen
induces a mixed Th1–Th2 response with low doses of
p17/p24 inducing more of a Th1 response, which changes
to a greater Th2 type response when higher doses of p17/
p24 are used. Although the inoculation with p17/p24 pro-
tein alone was not immunogenic in mice, we may find if
we use a higher dose with homologous boosts or adju-
vant, that a Gag-specific immune response is induced.
Results obtained using a classic western blot strip assay for
HIV antibodies also showed a clear boosting of the DNA-
induced response, apparently to a greater degree than
obtained by DNA prime-DNA boost (see Figure 6).
Our results highlight the potential of transient expression
in plants for the production of HIV-l vaccine-relevant pro-
teins. Until recently, transient expression through Agrobac-
terium-mediated infiltration was generally used only to
verify gene expression, and to validate small amounts of
recombinant proteins. However, it is now considered a
genuine protein expression strategy in its own right that
can potentially yield large amounts of protein
[7,13,56,57]. Additionally, the short production cycle can
reduce costs considerably compared to the equivalent
transgenic case. The use of post-transcriptional silencing
suppressors such as p19 and NSs [18], as well as increased
protein stability after targeting proteins to cellular
organelles, can further enhance the expression level. Fur-
thermore, technologies have been developed to extract
and purify antigens produced in plants for use in multi-
component vaccines or immunogenic presentation of
epitopes on VLPs or virions [7,13,56].
While many studies have been done to establish the
potential of transplastomics for recombinant protein pro-
duction, information on the use of plastid targeting tags
such as rbsc1-cTP in pharmaceutical protein production is
limited. However, a possible advantage lies in the fact that
translation of the targeted proteins occurs in the cyto-
plasm, and then the proteins are imported into chloro-
plasts: when they are inside the chloroplast, the targeted
proteins are then folded correctly,, making them more
appropriately immunogenic. Using transit peptide tags
might therefore overcome the limitations of using trans-
plastomics, which include product insolubility, a lack of
post-translational modifications, less established chloro-
plast transformation protocols and biosafety concerns of
the horizontal transfer of transgenes from chloroplasts of
transplastomics to bacteria under lab conditions [58].
Conclusion
We determined that it was feasible to produce vaccine-rel-
evant HIV-1 subtype C Gag-derived proteins in plants of
Nicotiana spp. by means of transient expression via recom-
binant A tumefaciens, rather than via rTMV or transgenic
expression. We demonstrated the positive effects on pro-
tein yield of plant codon optimisation, specific intracellu-
lar targeting, and protein composition. In particular, a
p17/p24 fusion protein accumulated to relatively high
levels in chloroplasts, was relatively easily partially puri-
fied from plants, and could be used to significantly boost
both cellular and humoral immune responses in mice
previously injected with an HIV DNA vaccine. This is the
most vaccine-relevant HIV protein so far expressed in
plants, and could have considerable potential.
Methods
Origin of DNA sequences
The HIV-1 gag gene used in these studies was from the
cloned South African HIV isolate Du422 which has been
used as the basis for South African HIV-1 subtype C vac-
cines (European Collection of Cell Cultures provisional
accession no. 01032114; GenBank accession. AF544010)
[3,4]. It was codon optimised for human and Nicotiana
spp. expression and synthesised by GENEART GmbH
(Germany). The capsid protein gene p24 and the p17/24
protein gene used in this work were derived from the Nico-
tiana spp. codon-optimised ngag gene.
Viral vector expression
The wtgag ORF was cloned into the TMV Geneware™ vec-
tor pBSG1057 (Large Scale Biology Corporation, Vacav-BMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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ille, Ca., USA) at PacI and XhoI sites to yield the clone
pBSGwtgag. The ngag  version was also cloned into
pBSG1057 to yield pBSGngag. A wild type p24 ORF
(wtp24) derived by PCR from wtgag as well as Nicotiana
spp. and human codon-optimised versions np24  and
hp24 were cloned into pBSG1057 at the same restriction
enzyme sites to yield the clones pBSGwtp24, pBSGnp24
and pBSGhp24. Recombinant viral RNA was transcribed
from the clones using the RiboMAX™ Large Scale RNA
Production System (T7) (Promega, Madison). The RNA
was rub-inoculated onto leaves of N. benthamiana plants
with gloved hands and a pinch of Celite (Merck, Ger-
many). Plants were grown at 22°C under a 16 h/8 h light/
dark cycle, monitored daily for TMV symptoms and leaves
sampled at 3 to 10 days post inoculation (dpi) to test for
Gag or p24 expression. Samples for electron microscopy
for the detection of Gag VLPs were prepared using crude
plant sap – plants were crushed in a minimal volume of 1
× PBS and the filtered extract clarified by centrifugation –
from N. benthamiana plants infected with pBSGwtgag and
pBSGngag RNA (10 dpi). Twenty microlitre amounts were
immunotrapped onto carbon-coated copper grids (200
mesh) coated with HIV-1 p17 antiserum (ARP431,
NIBSC). These were stained with 2% uranyl acetate and
viewed under a Zeiss S1109 transmission electron micro-
scope. Baculovirus-produced Gag VLPs were produced as
previously described [30] for comparison.
Agrobacterium tumefaciens-mediated transient 
expression
The ngag-derived gag, p24 and p17/24 ORFs were modified
by PCR to attach the appropriate restriction enzymes sites
to the 5' and 3'termini for cloning into the pTRA binary
vectors: these are three pPAM-derived (Genbank Acces-
sion number AY027531) binary vectors, pTRAc, pTRAkc-
ERH and pTRAkc-rbcs1-cTP [52], kindly provided by Dr
Rainer Fischer (Fraunhofer Institute, Aachen, Germany).
All three vectors have a cauliflower mosaic virus (CaMV)
35S promoter with a duplicated transcriptional enhancer,
a CaMV 35S polyadenylation signal and a chalcone syn-
thase 5' untranslated region for recombinant gene expres-
sion. Cloning into pTRAc results in cytoplasmic
localisation; pTRAkc-ERH has a KDEL ER retention signal,
while pTRAkc-rbcS1-cTP adds a chloroplast targeting sig-
nal from the small subunit of RUBISCO from Solanum
(rbcS1-cTP). The HIV-1 p24, p17/p24 and gag genes were
cloned into these vectors to yield 12 different constructs
(Table 2). The gene encoding the p19 suppressor protein
of Tomato bushy stunt virus (D Baulcombe, Sainsbury
Lab, John Innes Centre, Norwich) was amplified by PCR
with sense primer: 5' GGACGCGTTAGGTACATGGAACG
AGCTATACAA 3', and antisense primer: 5' TCTAGACTC-
GAGTTACTCGCTTTC TTTTTCG 3', digested Afl III/Xho I
and cloned into pTRAc, forming pTRAp19.
Two sets of clones were generated for the expression of
HIV p17/24 genes in plants, one with the myristylation
signal (p17/24-M) and the second lacking a myristylation
signal (p17/24-NM). The attachment site of myristate
occurs at the N terminal glycine [59] and this site was
mutated from GGT (glycine) to GCT (alanine) by PCR. To
generate appropriate constructs the p17/24 fusion
sequence was amplified by PCR from pTHGagC. The frag-
ments were cloned into the pTRA vectors to generate
pTRA-Cp17/p24-M and pTRA-Cp17/p24-NM, pTRA-
ERp17/p24-M and pTRA-ERp17/p24-NM, and pTRA-
CPTp17/p24-M and pTRA-CPTp17/p24-NM respectively
(Table 2).
Approximately 50 to 100 ng of recombinant plasmid was
electroporated into host A. tumefaciens
GV3101::pMP90RK cells as described by Maclean et al.
[52] Recombinant A. tumefaciens colonies were selected
on plates incubated at 27°C containing kanamycin (30
μg/ml), rifampicin (50 μg/ml) and carbenicillin (50 μg/
ml).
For infiltration, recombinant strains were grown up over-
night at 27°C with agitation in induction medium con-
taining LB and 10 mM MES (pH5.6) supplemented with
20 μM acetosyringone, kanamycin (30 μg/ml), rifampicin
(50 μg/ml) and carbenicillin (50 μg/ml). Cells were pel-
leted at 1000 g, resuspended in infiltration medium con-
taining 10 mM MES and 1 M MgCl2  (pH 5.6)
supplemented with 200 μM acetosyringone and diluted in
infiltration medium to an OD600 of 0.25. After incubation
at 22°C for 2 hours, cells were infiltrated by injection (1
ml syringe) or vacuum (-90 KPa for 1 min) into whole,
uprooted N. benthamiana plants. Plants were co-infiltrated
with  A. tumefaciens LBA4404 (diluted in infiltration
medium to an OD600 of 0.25) containing a silencing sup-
pressor pBIN-NSs (provided by Marcel Prins, Laboratory
of Virology, Wageningen, The Netherlands) which
enhances transient protein expression by suppressing post
transcriptional gene silencing [60]. This strain was simi-
larly grown up overnight at 27°C with agitation in induc-
tion medium containing LB and 10 mM MES (pH 5.6)
supplemented with 20 μM acetosyringone, kanamycin
(30 μg/ml), rifampicin (50 μg/ml) and 2 mM MgSO4 to
prevent the cells from clumping. Infiltrated plants were re-
planted, grown at 22°C under a 16 h/8 h light/dark cycle
and subsequently harvested at 3 dpi.
Plant transformation
This work was carried out using 2–4 week-old Nicotiana
tabacum cv. Petite Havana SRI plants grown in a green-
house under a 16 hr light and 8 hr dark photoperiod at
light intensity of 60–80 μE/m2/s and 22°C.BMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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To generate transgenic plants, the recombinant Agrobacte-
rium  cultures containing the pTRA-CPTp17/p24-M and
pTRA-ERp17/p24-M constructs were used to transform
tobacco (N. tabacum cv. Petite Havana) by leaf disc trans-
formation as described by [61]. Briefly, leaf discs (0.5 cm
× 0.5 cm) were dipped in Agrobacterium overnight culture
(OD600 = 0.6), regenerated under kanamycin selection (30
μg/ml) and rooted plantlets hardened off before being
grown in a greenhouse under conditions described above.
Immunoblotting
For western blotting, plant samples were ground in SDS-
PAGE loading buffer and the proteins were separated by
SDS-PAGE as described [52]. Proteins were transferred
onto a nylon membrane and then challenged with rabbit
polyclonal anti-p24 and goat anti-rabbit IgG (Sigma).
ELISA analysis
For the plants infiltrated with p24, p17/24 and Pr55Gag
constructs, six leaf discs (made using a 1.5 ml microfuge
tube cap) per plant were harvested and ground up in 300
μl of extraction buffer (4 M urea, 100 mM DTT [18]) and
liquid nitrogen. Samples were centrifuged for 10 min at
10000 rpm and the supernatant was used for ELISA with
the appropriate sample dilutions. To detect the presence
of HIV p17/24 a Vironostika® HIV-1 antigen Microelisa kit
(bioMérieux, Netherlands) was used. The kit is based on
measuring HIV antigens using p24 murine monoclonal
antibodies. For comparison, calculated antigen concentra-
tions in the samples were normalised to the fresh leaf
weight to obtain the yield of p24 per kg.
Preparation of recombinant HIV-1 p17/p24-M
A. tumefaciens GV3101::pMP90RK cultures containing the
pTRA-CTPp17/p24-M or pTRA-P19 clones were grown as
described above. The Agrobacterium  suspensions were
diluted in infiltration medium to OD600 1.0, and were
kept at 25°C for 2 h, then diluted and combined in infil-
tration medium, both to a final OD600 of 0.25. Whole N.
benthamiana plants (3–4-weeks old) were vacuum-infil-
trated: the plants were submerged into the bacterial sus-
pension and subjected to a vacuum of -80 kPa for 2–5
min, with occasional agitation to release trapped air bub-
bles. The vacuum was released rapidly (~10 kPa/s). The
plants were grown for 8 days under conditions of 16 h
light, 8 h dark, 22°C.
Approximately 200 g of N. benthamiana leaves agroinfil-
trated with pTRA-CPTp17/p24-M were harvested at 8 dpi
and homogenised in a Waring blender in extraction
bufffer (50 mM phosphate buffer containing 0.5 M NaCl,
5% glycerol, 0.05% Triton-X100, 1% sodium metabisul-
phite, pH 7.2). After 4 h incubation at 4°C the extract was
centrifuged at 6 000 rpm for 20 min and the supernatant
collected. PEG 6000 was added to 2% w/v, and the pH of
the extract was adjusted to 7.2 with NaOH. The centrifu-
gation was repeated and the supernatant was then concen-
trated 10-fold using a 10 kDa cut-off hollow-fibre column
(GE Healthcare), and subjected to a 4 volume buffer
exchange using a 50 mM phosphate buffer containing 0.5
M NaCl, 5% glycerol, 0.1 M ascorbic acid, at pH 7.2. Total
leaf protein was determined to be 13 mg/ml and the p24
content determined to be 84 μg/ml by ELISA as described
above.
The protein was assayed for purity by fractionation on
10% Coomassie-stained SDS-PA gels.
pTHGagC and p17/p24 inoculum preparation
The DNA vaccine pTHGagC that expresses the Du422
HIV-1 subtype C Gag [4], was manufactured by Aldevron,
Fargo, ND, USA and resuspended at 1 mg DNA/ml saline.
Leaves infiltrated with p17/p24 were resuspended at 13
mg leaf protein/ml and determined to contain 84 μg p24/
ml by a p24 ELISA assay (Vironostika® HIV-1 antigen
ELISA). A control with 13 mg leaf protein/ml was pre-
pared from leaves that did not contain p17/p24.
Immunization of BALB/c mice
Female BALB/c mice (8 – 10 weeks old) were divided into
8 groups with 5 mice per group. pTHGagC (100 μg DNA/
100 μl saline) was given by injecting 50 μl into each tibi-
alis anterior muscle. Leaf protein diluted in saline to give
either 100 μg leaf protein/100 μl saline or 10 μg leaf pro-
tein/100 μl saline (containing the equivalent of 646 ng or
64 ng p17/p24 respectively) or control leaf protein (100
μg/100 μl saline) not containing p17/p24 was given intra-
muscularly by injecting 50 μl of the dose into each quad-
riceps muscle. pTHGagC was given as a primary
inoculation to mouse groups 1 – 5 on day 0 while groups
6 – 8 were left unvaccinated until day 28. Group 1
received no further vaccination. On day 28 group 2 was
given a booster injection of pTHGagC, groups 3 and 4
received either 646 ng or 64 ng p17/p24 protein and
group 5 received 100 μg control leaf protein. 646 ng or 64
ng p17/p24 protein was given to groups 6 and 7 and
group 8 received control leaf protein (100 μg) on day 28.
All mouse groups were sacrificed on day 40.
IFN-γ ELISPOT assay
A single cell suspension of splenocytes was prepared from
spleens harvested on day 40 and pooled from 5 mice per
group. IFN-γ ELISPOT responses were measured using a
mouse IFN-γ ELISPOT set (BD Pharmingen). Splenocytes
were plated in triplicate at 5 × 105/well in a final volume
of 200 μl R10 culture medium (RPMI with 10% heat inac-
tivated FCS, Gibco, containing 15 mM β-mercaptoetha-
nol, 100 U penicillin per ml, and 100 μg streptomycin).
The peptides (>95% pure, Bachem, Switzerland) GagCD8
AMQMLKDTI and GagCD4 NPPIPVGRIYKRWIILGLNKBMC Biotechnology 2008, 8:53 http://www.biomedcentral.com/1472-6750/8/53
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were used as stimuli in the assay at a final concentration
of 4μg/ml. Reactions containing an irrelevant H-2Kd bind-
ing peptide TYSTVASSL (obtained from Elizabeth Reap,
AlphaVax) or without peptide served as background con-
trols. Spots were detected with the detection antibody at
22 h, developed with Nova Red then counted using a CTL
Analyzer (Cellular Technology, OH, USA) with Immuno-
spot Version 3.0 software. The average number of spots in
triplicate wells was calculated and results are expressed as
the average number of spot-forming units (SFU) per 106
splenocytes ± the standard deviation (SD). For each group
of mice the average background spots obtained in the
absence of peptide and in the presence of the irrelevant
peptide plus one standard deviation of this average was
considered as the cut-off for a positive response.
Antibody measurement by ELISA and western blot
To measure Gag specific antibodies in mouse serum,
enzyme linked immunosorbent assay (ELISA) plates were
coated with recombinant Gag protein (Quality Biologi-
cals) at 1 μg/ml 0.1 M bicarbonate buffer (pH 9.5) over-
night at 4°C. Plates were blocked with 10% FCS in PBS for
2 h at RT after which a 1:1000 dilution of serum samples
pooled from 5 mice per group was added to the wells for
a further 2 h at RT. A panel of goat-anti mouse antibodies
specific for total IgG, IgG1, IgG2a, IgG2b and IgG3,
obtained from Southern Biotechnology Associates (Bir-
mingham, AL) as peroxidase-conjugated antibodies was
used as per the manufacturer's instructions. Peroxidase
substrate was reacted with o-phenylendiamine dihydro-
chloride (Sigma) and reactions at RT were stopped 10 min
later with 2 N H2SO4 and the absorbance at 450 nm read
on a Labsystems Multiskan Plus plate reader. The absorb-
ance value for total IgG, IgG1, IgG2a, IgG2b and IgG3
with a 1:1000 dilution of serum taken prior to inoculation
(pre-bleed value) was less than 0.033 ± 0.001 for all
groups from which an absorbance value of 0.066 was
decided as the cut off value for a positive response.
A commercial New LAV Blot I (BioRad) was used accord-
ing to the manufacturer's instructions to determine the
specificity of the antibodies in mouse serum. Mouse
serum was used at a 1:40 dilution and antibody content
detected with goat anti-mouse IgG conjugated to alkaline
phosphatase.
Statistical analysis
Statistical analysis was performed using the Student's t
test.
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